Back to results
US 2022/0220174 A1Published application
Bnip3 peptides for treatment of reperfusion injury
AssigneeBimyo GmbH
InventorsTienush RASSAF, Ulrike HENDGEN-COTTA
Life of this patent
Estimating the term…
Abstract
The invention provides peptides capable of inhibiting the individual activity and inter-pathway communication of BNIP3, BAX and mitochondria. The peptides can be used in methods of treating a disease or condition in a subject in which it is desirable to prevent cell damage and cell death.
Claims19
A peptide comprising
- (i) a cellular uptake signal;
- and
- (ii) a BNIP3 fragment comprising positions 13 to 20 of BNIP3 or an amino acid sequence derived therefrom;
- wherein the peptide has a length of 50 amino acids or less.
1 more element
A method of screening for a compound suitable for prevention of reperfusion injury and/or mitochondria-induced disorders and/or cancer therapy-induced cardiotoxicity, comprising
- (i) providing one or more candidate compounds;
- (ii) determining the ability of the candidate compounds to interfere with the binding of BNI P3 and BAX;
- (iii) selecting those candidate compounds which interfere with the binding of BNIP3 and BAX.
Dependencies are inferred from the claim text.